DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
Conference Call details:
Date:
Wednesday, May 14, 2025
Time:
8:00 AM ET / 7:00 AM CT
Web access:
https://app.webinar.net/24NpV0mjklG
Dial In:
(800) 836-8184
Conference ID:
93262
Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company's website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 21, 2025, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 93262#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250507348121/en/
Contacts
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Why Comcast Stock Popped Today
Key Points Comcast beat on sales and beat on earnings this morning. GAAP profit and free cash flow both tripled year over year. Comcast didn't give guidance -- and could surprise Wall Street again this year. 10 stocks we like better than Comcast › Shares of cable and internet giant Comcast (NASDAQ: CMCSA) are on the rise this afternoon, up 2.6% through 1:10 p.m. ET after beating on earnings in the morning. Heading into Comcast's Q2 report, analysts forecast the company would earn $1.18 per share, adjusted for one-time items, on $29.8 billion in sales. Instead, Comcast earned $1.25 per share on sales of $30.3 billion. Comcast Q2 earnings Sales inched only 2% higher year over year, and adjusted net income was up only 3% -- but earnings per share as calculated according to generally accepted accounting principles (GAAP) nearly tripled to an astounding $2.98, and free cash flow more than tripled to $4.5 billion. That alone would more than explain investors' enthusiasm today. Is Comcast stock a buy? Comcast didn't give guidance for how the rest of the year will play out, and analysts who follow the stock might be in for a surprise. According to Yahoo! Finance data, earnings are only supposed to grow a penny (year over year) in Q3, and to decline in Q4 -- resulting in full-year 2025 profit declining $0.02 to $4.31 per share. Comcast's tremendous Q2, however, just delivered nearly three-quarters of the year's forecast profit in a single quarter, setting up Comcast to potentially thrash expectations by the end of this year. Meanwhile, Comcast stock trades for a mere 5 times trailing earnings -- which might be the right price if earnings are shrinking, but could be incredibly cheap if earnings grow like it looks like they're going to. Even factoring Comcast's $100 billion-plus debt load into the picture, a stock that costs 5.3x earnings, pays a 4.1% dividend, and shows any growth at all would seem cheap to me. Comcast stock is a buy. Should you buy stock in Comcast right now? Before you buy stock in Comcast, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Comcast wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Comcast. The Motley Fool has a disclosure policy. Why Comcast Stock Popped Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best strong buy stocks to buy under $10. In a report released on July 25, Les Sulewski from Truist Financial maintained a Buy rating on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a price target of $8.00. A pharmaceutical laboratory filled with shelves of medicines, highlighting the company's specialty drug production. The rating update followed Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) announcement of certain unaudited preliminary financial results for fiscal Q2 on July 21. The company has plans to report the actual Q2 2025 results on August 5. The unaudited preliminary financial results for the quarter showed a net revenue of $720 million to $730 million, suggesting an increase of around 3% versus the same period last year. Adjusted EBITDA rose around 13% to $180 million to $185 million, with income before income taxes of $45 million to $56 million, compared to $20 million in the same period in 2024. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a medicine company that provides pharmaceuticals. The company's product portfolio encompasses biosciences, specialty, generics, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments. While we acknowledge the potential of AMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
36 minutes ago
- Yahoo
Ethereum ETFs, Treasury Companies Now Hold Over $32B In ETH: Here's What's Driving The Frenzy
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Corporate treasuries and spot ETFs are rapidly consolidating their hold on Ethereum (CRYPTO: ETH), with combined on-chain and off-chain holdings now surpassing $32 billion. Data compiled by SER shows that 64 entities, spanning publicly listed firms, exchanges, DeFi protocols, nonprofits and governments, collectively hold 2.73 million ETH in their treasuries, valued at over $10.5 billion. Invest in Gold American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Thor Metals Group: Best Overall Gold IRA This marks a notable shift in asset allocation strategies, particularly as companies like Bitmine Immersion Tech (AMEX:BMNR), SharpLink Gaming (NASDAQ:SBET), and Ether Machine now individually surpass the Ethereum Foundation in ETH holdings. Trending: 7,000+ investors have joined Timeplast's mission to eliminate microplastics— Bitmine alone controls 625,000 ETH, followed by SharpLink with 438,200 ETH and Ether Machine with 334,800 ETH. U.S. spot Ethereum ETFs have seen explosive growth, with net inflows totaling $5.38 billion over a 19-day streak that began on July 3. This matches a prior record streak from May but significantly exceeds it in dollar terms. BlackRock's (NASDAQ:ETHA) fund leads the pack, pulling in $4.19 billion during this run and controlling over 3 million ETH — about 2.5% of total ETH supply. Altogether, U.S. spot Ethereum ETFs now hold approximately 5.7 million ETH, valued near $22 billion. That figure represents 4.7% of Ethereum's circulating supply, per data from CoinGlass. These allocations make ETFs the single largest collective holder of ETH assets, outpacing even corporate It Matters: This trend of institutional accumulation has been supported by recent regulatory shifts. On Tuesday, the U.S. SEC approved in-kind redemptions for crypto ETFs, allowing authorized participants to exchange ETH and BTC directly for ETF shares, rather than cash, a move that aligns the structure of crypto funds with traditional markets and improves tax efficiency. Additionally, BlackRock received acknowledgment from the SEC for its 19b-4 filing to enable staking within its ETH ETF, setting the stage for a new layer of yield-generating exposure for institutional investors. Standard Chartered's digital assets head Geoffrey Kendrick predicts ETH treasuries could grow to control as much as 10% of the total supply, citing yield-generating opportunities like staking and deeper DeFi integration. However, analysts at Bernstein caution that staking strategies, while lucrative, come with liquidity and smart contract risk. The current momentum underscores a new phase for Ethereum, not only as a tech stack for decentralized applications but increasingly as a yield-bearing, institutionally held financial asset. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image: Shutterstock This article Ethereum ETFs, Treasury Companies Now Hold Over $32B In ETH: Here's What's Driving The Frenzy originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
